DNA composition and uses thereof

Details DNA composition and uses thereof DNA composition and uses thereof

2007-03-27

2007-03-27

Campell, Bruce R. (Department: 1648)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S320100

Reexamination Certificate

active

10757343

ABSTRACT:
A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3′ LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.

REFERENCES:
patent: 6348450 (2002-02-01), Tang et al.
patent: 6420176 (2002-07-01), Lisziewicz et al.
patent: WO 99/43350 (1999-09-01), None
patent: PCT/US02/16546 (2002-11-01), None
Robinson, H.L. (2002). “New hope for an AIDS vaccine.” Nature Rev Immunol 2(4): 239-250.
Fields, B. N. and D. M. Knipe, Eds. (1990). Virology. Retroviridae and their replication. New York, Raven Press, LTD.
Chen, S. S., A. A. Ferrante, et al. (1996). “Characterization of an envelope mutant of HIV-1 that interferes with viral infectivity.” Virology 226(2): 260-8.
Smythe, J. A., D. Sun, et al. (1994). “A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection.” Proc Natl Acad Sci U S A 91(9): 3657-61.
Yung, E., M. Sorin, et al. (2001). “Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1,” Nat Med 7(8): 920-6.
Plavec, I., M. Agarwal, et al. (1997). “High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.” Gene Ther 4(2): 128-39.
Fraisier, C., D. A. Abraham, et al. (1998). “Inhibition of Tat-mediated transactivation and HIV replication with Tat mutatn and repressor domain fusion proteins.” Gene Ther 5(7): 946-54.
Sawaya, B. E., K. Khalili, et al. (2000). “Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.” J Virol 74(10): 4877-81.
Gitlin, S. D., P. F. Lindholm, et al. (1991). “Transdominant human T-cell lymphotropic virus type I TAX1 mutant that fails to localize to the nucleus.” J Virol 65(5): 2612-21.
Bohnlein, S., F. P. Pirker, et al. (1991). “Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function.” J Virol 65(1): 81-8.
Smith, C. A. and N. A. DeLuca (1992). “Transdominant inhibition of herpes simplex virus growth in transgenic mice.” Virology 191(2): 581-8.
Chen, J., C. Panagiotidis, et al. (1992). “Multimerization of ICP0, a herpes simplex virus immediate-early protein.” J Virol 66(9): 5598-602.
Piccinini, G., A. Foli, et al. (2002). “Complimentary antiviral efficacy of hydroxyurea and protease inhibitors in human immunideficiency virus-infected dendridic cells and lyphocytes.” J Virol 76(5): 2274-8.
Jayan, G.C., P. Cordelier, et al. (2001). “SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.” Gene Ther 8(13): 1033-42.
Frankel, S.S., K. Tenner-Racz, et al. (1997). “Active replication of HIV-1 at the lymphoepithelial surface of the tonsil.” Am J Pathol 151(1): 89-96.
Jamieson, B. D., G. M. Aldrovandi, et al. (1994). “Requirement of human imminuodeficiency virus type 1 nef for in vivo replication and pathogenicity.” J Virol 68(6): 3478-85.
Aldrovandi, G. M., L. Gao, et al. (1998). “Regions of human immunodificiency virus type 1 nef required for function in vivo.” J Virol 72(9): 7032-9.
Geffin, R., D. Wolf, et al. (2000). “Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors.” AIDS Res Hum Retroviruses 16(17): 1855-68.
Lisziewicz, J., D. I. Gabrilovich, et al. (2001). “Induction of potent human immunodificiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells.” J Virol 75(16): 7621-8.
Zufferey, R., T. Dull, et al. (1998). “Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.” J Virol 72(12): 9873-80.
Vicenzi, E., D. S. Dimitrov, et al. (1994). “An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.” J Virol 68(12): 7879-90.
Zhou, H., G. J. Raniey, et al. (2001). “Substrate sequence selection by retroviral integrase.” J Virol 75(3): 1359-70.
Murphy, J. E. and S. P. Goff (1989) “Construction and analysis of deletion mutations in the U5 region of Moloney murine luekemia virus: effects on RNA packaging and revers transcription.” J Virol 63(1): 319-27.
Lisziewicz, J., E. Rosenberg, et al. (1999). “Control of HIV despite the discontinuation of antiretroviral therapy.” N Engl J Med 340(21): 1643-4.
Lori, F., M. G. Lewis, et al. (2000). “Control of SIV rebound through structured treatment interruptions during early infection.” Science 290(5496): 1591-3.
Rosenberg, E. S., M. Altfeld, et al. (2000). “Immune control of HIV-1 after early treatment of acute infection.” Nature 407(6803): 523-6.
Barouch, D. H., J. Kuntsman, et al. (2002). “Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.” Nature 415(6869): 335-9.
Trono, D., M. B. Feinberg, et al. (1989). “HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus.” Cell 59: 113-120.
Grant, E. P., M. T. Michalek, et al. (1995). “Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation.” J Immunol 155(8): 3750-8.

Affiliated with

Also associated with

Rating

DNA composition and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA composition and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA composition and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3778809